Study record
TA-65 and telomere length: systematic review and meta-analysis of 8 RCTs (Su et al., 2025)
Human — telomere-length meta-analysis of randomized trials
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 3 — Human RCT — telomere-length / telomerase-activity biomarker endpoint
Record verify: verified against primary source
| Design | PRISMA-guided systematic review and meta-analysis of 8 randomized controlled trials (n=750) |
| PMID | 41286474 |
| PMCID | PMC12644169 |
| DOI | 10.1007/s10565-025-10115-6 |
| Citation status | PMID, PMCID and DOI verified against Europe PMC 2026-08-08: Su X, Wang C, Gou Z, Qu Y. 'Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis.' Cell Biol Toxicol 2025;41(1):155. Electronic publication 2025-11-25, PubMed-indexed 2025-11-25, open access (CC BY-NC-ND). Previously carried on this site as an unconfirmed reference; the primary record is now confirmed. |
Five-qualifier claim
| Species / population | Pooled analysis of 8 randomized controlled trials, n=750 participants, mean age 63.3 years. |
| Exposure, route, schedule | Oral TA-65 across the included trials, 10-50 mg/day. Dose-response across that range was not significant (p>0.05). |
| Comparator / duration | Placebo-controlled randomized trials pooled with random-effects models; GRADE evidence grading applied. Safety analysed over 12 months (n=487). |
| Endpoint / numeric result | Telomere length increased: SMD 0.47 (95% CI 0.31-0.62; p<0.00001), with a larger effect in adults over 60 (SMD 0.63 vs 0.36; p=0.03). But the effect did not carry through to function or inflammation: frailty SMD 0.09 (p=0.15) and CRP/IL-6 SMD -0.11 (p=0.07), neither significant. The authors call this a telomere-function disconnect. Industry-funded trials reported a larger effect than independent ones (SMD 0.63 vs 0.40; p=0.03). Safety: mild gastrointestinal toxicity in 12.4% (nausea 7.1%, abdominal discomfort 5.3%), no severe adverse events over 12 months. |
| What it did NOT establish | This is a meta-analysis of a contested biomarker, not a lifespan or clinical-outcome result. Telomere elongation was measured; benefit to the person was not. The pooled trials show no improvement in frailty or inflammation, so a longer telomere here is not evidence of a healthier or longer life. The authors state that long-term carcinogenic potential remains unaddressed, and that industry funding was associated with larger reported effects. |
Interventions
Primary reference
https://pubmed.ncbi.nlm.nih.gov/41286474/
Each identifier above was confirmed against the primary record; the citation status names the source and the date. An identifier that could not be confirmed is left empty and named as such in the record, never filled in from a secondary source.